JP2015510926A5 - - Google Patents

Download PDF

Info

Publication number
JP2015510926A5
JP2015510926A5 JP2015501032A JP2015501032A JP2015510926A5 JP 2015510926 A5 JP2015510926 A5 JP 2015510926A5 JP 2015501032 A JP2015501032 A JP 2015501032A JP 2015501032 A JP2015501032 A JP 2015501032A JP 2015510926 A5 JP2015510926 A5 JP 2015510926A5
Authority
JP
Japan
Prior art keywords
composition
bcp
schizophrenia
treat
patient suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015501032A
Other languages
English (en)
Japanese (ja)
Other versions
JP6326563B2 (ja
JP2015510926A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/052182 external-priority patent/WO2013140342A1/en
Publication of JP2015510926A publication Critical patent/JP2015510926A/ja
Publication of JP2015510926A5 publication Critical patent/JP2015510926A5/ja
Application granted granted Critical
Publication of JP6326563B2 publication Critical patent/JP6326563B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015501032A 2012-03-19 2013-03-19 β−カリオフィレンとＣＢ２受容体アゴニストを用いた精神病の治療 Expired - Fee Related JP6326563B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612411P 2012-03-19 2012-03-19
US61/612,411 2012-03-19
PCT/IB2013/052182 WO2013140342A1 (en) 2012-03-19 2013-03-19 Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists

Publications (3)

Publication Number Publication Date
JP2015510926A JP2015510926A (ja) 2015-04-13
JP2015510926A5 true JP2015510926A5 (enExample) 2016-05-12
JP6326563B2 JP6326563B2 (ja) 2018-05-23

Family

ID=49221922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501032A Expired - Fee Related JP6326563B2 (ja) 2012-03-19 2013-03-19 β−カリオフィレンとＣＢ２受容体アゴニストを用いた精神病の治療

Country Status (4)

Country Link
US (4) US20150051299A1 (enExample)
EP (1) EP2827846B1 (enExample)
JP (1) JP6326563B2 (enExample)
WO (1) WO2013140342A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013140342A1 (en) 2012-03-19 2013-09-26 Ariel-University Research And Development Company, Ltd. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
EP3265081A4 (en) 2015-03-02 2018-11-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
JP6397792B2 (ja) * 2015-04-10 2018-09-26 ポッカサッポロフード＆ビバレッジ株式会社 飲料
US20190070124A1 (en) * 2016-03-04 2019-03-07 Sharon Anavi-Goffer Compositions of cb2 receptor selective agonists for treatment of mental disorders
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
US20190241962A1 (en) * 2016-10-02 2019-08-08 Sharon Anavi-Goffer Genetic susceptibility diagnosis and treatment of mental disorders
US20230200435A1 (en) * 2020-03-10 2023-06-29 Kinki University Caryophyllene-containing agent or composition and various applications thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
US20070154534A1 (en) * 2003-03-12 2007-07-05 Sheitman Brian B Use of secretin in the treatment of schizophrenia
WO2005121140A1 (en) * 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
MX2007002116A (es) * 2004-10-01 2007-10-16 Ache Lab Farmaceuticos Sa Uso de cariofilinas en la fabricacion de medicamentos y tratamiento de condiciones corporales de inflamacion y dolor inflamatorio.
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
DK1903866T3 (en) * 2005-11-07 2016-07-25 Murty Pharmaceuticals Inc Improved release of tetrahydrocannabinol
BRPI0711064A2 (pt) * 2006-04-27 2011-08-23 Solvay Pharm Gmbh composições farmacêuticas compreendendo moduladores do receptor de canabinóides cbx e moduladores do canal de potássio
CA2688570A1 (en) * 2007-05-31 2008-12-04 F.P.L. Pharma Inc. Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof
KR20110073653A (ko) 2009-12-24 2011-06-30 충북대학교 산학협력단 4-ｏ-메틸호노키올을 유효 성분으로 함유하는 항-불안 예방 및 치료용 의약 조성물
WO2013140342A1 (en) 2012-03-19 2013-09-26 Ariel-University Research And Development Company, Ltd. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
WO2014170902A1 (en) 2013-04-17 2014-10-23 Ariel - University Research And Development Company, Ltd. Cb2 receptor ligands for the treatment of psychiatric disorders
US20190241962A1 (en) 2016-10-02 2019-08-08 Sharon Anavi-Goffer Genetic susceptibility diagnosis and treatment of mental disorders
EP3558281A4 (en) 2016-12-15 2020-07-08 Sharon Anavi-Goffer TREATMENT OF MENTAL DISORDERS, MOVEMENT AND BEHAVIOR

Similar Documents

Publication Publication Date Title
JP2015510926A5 (enExample)
JP2016539144A5 (enExample)
JP2015537003A5 (enExample)
CL2012001133A1 (es) Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo.
JP2011508765A5 (enExample)
JP2010535220A5 (enExample)
TW201306840A (zh) 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌□反其鹽用於治療精神分裂症的方法
GEP20125379B (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
JP2012524112A5 (enExample)
MX2009011619A (es) Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.
HRP20201916T1 (hr) Trifluorometil supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
CA2671954A1 (en) Methods for treating or preventing symptoms of hormonal variations
IL188643A (en) Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production.
UA107353C2 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
RU2011137131A (ru) Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха
WO2008006795A3 (en) Indole compounds
JP2010516701A5 (enExample)
JP2015510916A5 (enExample)
JP2015510928A5 (enExample)
Findling et al. The antipsychotics: a pediatric perspective
JP2017520588A5 (enExample)
MD4538B1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
PH12017501831A1 (en) Pharmaceutical compositions for oral administration
JP2016514688A5 (enExample)